Genome-wide association studies identify disease mechanisms in age-related macular degeneration by Wright, Alan F & Barlow, Paul N
  
 
 
 
Edinburgh Research Explorer 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Genome-wide association studies identify disease mechanisms
in age-related macular degeneration
Citation for published version:
Wright, AF & Barlow, PN 2018, 'Genome-wide association studies identify disease mechanisms in age-
related macular degeneration', Ophthalmology, vol. 125, no. 7, pp. 962-964.
https://doi.org/10.1016/j.ophtha.2018.03.034
Digital Object Identifier (DOI):
10.1016/j.ophtha.2018.03.034
Link:
Link to publication record in Edinburgh Research Explorer
Document Version:
Peer reviewed version
Published In:
Ophthalmology
General rights
Copyright for the publications made accessible via the Edinburgh Research Explorer is retained by the author(s)
and / or other copyright owners and it is a condition of accessing these publications that users recognise and
abide by the legal requirements associated with these rights.
Take down policy
The University of Edinburgh has made every reasonable effort to ensure that Edinburgh Research Explorer
content complies with UK legislation. If you believe that the public display of this file breaches copyright please
contact openaccess@ed.ac.uk providing details, and we will remove access to the work immediately and
investigate your claim.
Download date: 12. Sep. 2019
1 
 
Barlow_Wright_150318_FINAL REVISION_clean copy 
 
 
 
 
 
 Genome-wide association studies identify disease mechanisms in age-related macular 
degeneration 
 
 
Alan F. Wright1 and Paul N. Barlow2 
   
 
1 MRC Institute of Genetics and Molecular Medicine, University of Edinburgh, Crewe Road, 
Edinburgh EH4 2XU, UK; 2 School of Chemistry, Joseph Black Bldg., University of Edinburgh, 
David Brewster Rd., Edinburgh EH9 3FJ, UK 
 
 
  
2 
 
Separating causal from confounding associations with disease has been a long-standing 
problem in epidemiology. The situation improved when it became feasible to perform 
genome-wide association studies (GWAS): genotyping of large case-control cohorts at 
several million single-nucleotide polymorphisms (SNPs) spread across the genome, in an 
unbiased screen for association (i.e. with no prior hypothesis). A key factor in their success 
was the use of stringent statistical thresholds to control for the numerous tests. Since 
genotypes are randomly distributed at meiosis, predate most traits and remain stable 
throughout life, they are not generally subject to confounding influences and so have 
provided robust and causal associations. GWAS also confirmed classical genetic theory 
stating that the majority of complex traits are influenced by innumerable variants with tiny 
individual effects. A recent extension of this theory, the “omnigenic” model, proposes that 
most traits are influenced by variants in a limited set of “core” genes, with direct and 
biologically interpretable effects, alongside more numerous “peripheral” genes, mostly with 
very small effects and acting through inter-connected regulatory networks.1 In fact, 
peripheral rather than core variants account for most trait heritability because, despite their 
small effects, there are over 100 times more of them. Peripheral variants lie outside coding 
regions and individually provide limited insights into trait biology. Indeed most are only 
detectable collectively. As an example, >100,000 SNPs are estimated to show independent 
causal effects on human height1, the vast majority exerting only tiny “peripheral” effects 
and providing limited biological insights.1 Given these considerations, what insights have 
been gained from GWAS in age-related macular degeneration (AMD)?   
On page xx, Lores-Motta et al.2 describe two new GWAS associations that confirm a core 
pathway and illuminate AMD pathogenesis. Genetic associations in AMD were amongst the 
first fruits of the GWAS approach, helped by uncharacteristically strong effects.3 One of 
these was attributed to a SNP (rs1061170) in the complement factor H gene (CFH), causing a 
Tyr402His substitution3. This may compromise the ability of its product, the soluble 
glycoprotein complement factor H (CFH), to suppress activation of complement on the 
surfaces of host (self) tissues while allowing complement to proceed unchecked on foreign 
surfaces (Fig. 1).4 Additional, independent, missense CFH SNPs that likely impact on CFH 
function were also reported. Other AMD-associated SNPs lay in non-coding, presumed 
regulatory, regions. Rare but more highly penetrant variants of CFH were later found in 
small subsets of AMD subjects. Unfortunately, while GWAS associations are statistically 
robust and indicative of causal associations, they don’t always indicate the precise 
nucleotides responsible. This is a particular problem in the CFH region, where there is a 
strong tendency for neighbouring nucleotides to be co-inherited in blocks that are only 
rarely separated by recombination (this is called linkage disequilibrium).  
A dysfunctional complement pathway in AMD was independently supported by 
immunohistochemistry showing that CFH and other complement components were present 
in drusen, a hallmark of AMD. Subsequently, other complement encoding genes (C3, factor 
B, factor I, C9, vitronectin) were associated with AMD in further and bigger GWAS, the 
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largest of which included >16,000 advanced AMD cases and ~18,000 controls.5 Complement 
pathway variants collectively accounted for about one-third of AMD risk.5 When the 
collective effect of genome-wide SNPs in AMD was partitioned into functional subsets, the 
most significant contribution came from ~1,300 SNPs in and around genes influencing 
complement biology.6 Together, the results pointed to a causal role for increased 
complement activation in AMD.  
These exciting findings stimulated a high level of translational and commercial activity but 
uncertainty remains over the relative importance of systemic versus local complement 
activation in AMD. While most complement genes are strongly expressed by the liver and 
encode proteins that circulate at quite high levels in the blood, other sources of 
complement proteins include the cells lying on either side of Bruch’s membrane (Fig. 1). This 
raises the key question of where to target therapeutic intervention. While systemic 
activation could damage the choriocapillary endothelium, local retinal or choroidal 
dysregulation might contribute most to retinal pigment epithelial (RPE) damage or drusen 
formation. 
The case for systemic complement activation was strengthened by studies of the 
“complotype” or joint effects of common functional variants in the CFH, CFB and C3 genes.7  
When combined, these showed up to six-fold variation in complement activation measured 
in vitro. Complotype is thus likely to influence an individual’s systemic complement 
activation. But a similar effect of complotype might be manifested in the eye, depending on 
the local levels of the various proteins, which remain to be established. Those liver 
transplant recipients who develop AMD reportedly carry the recipient rather than donor 
CFH Y402H risk allele, suggesting that local complement activation in the eye trumps 
systemic activation.8 
Other evidence supporting the primacy of systemic complement activation stems from the 
finding that complement activation end-products are elevated in patients’ blood.8 C3d is a 
stable proteolytic fragment of C3 and the endpoint of successive cleavages beginning with 
C3 cleavage to C3b, the key step in complement cascade activation (Fig. 1).9 C3b’s short-
lived thioester group either hydrolyses or binds covalently to nearby surfaces.  C3b, in fluid 
phase or on surfaces, is eventually inactivated by cleavage to iC3b and then to C3dg and 
finally C3d. Surface-tethered C3d can remain resident for an extended time. The ratio 
between serum concentrations of C3d and C3 is used as a proxy for systemic complement 
activation.2 Note that this ratio takes no account of potentially large amounts of C3d bound 
to cellular and other surfaces. Hence it reflects C3 consumption and fluid-phase activation 
but does not report directly on surface complement activation. 
Lores-Motta et al.2 address the role of systemic complement activation by reporting a GWAS 
of serum C3d/C3 ratios. The authors studied 717 AMD cases and 831 controls in a discovery 
cohort and confirmed their findings in a smaller replication cohort. No genetic variants 
outside a cluster of genes on chromosome 1, which includes CFH and five protein-coding 
CFH-related genes (CFHR1-5), showed significant association with C3d/C3. Of the two 
independent variants that did show genome-wide significant associations with C3d/C3, one 
(the strongest) was a coding variant in exon 14 of the CFH gene (rs3753396) that did not 
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change the amino acid sequence. The other was a non-coding SNP (rs6685931) in the CFHR4 
gene. Like other CFH-related proteins, CFHR4 antagonises the action of CFH, thus potentially 
promoting complement activation10, although its serum levels are 10-30-fold lower than 
those of CFH. Interestingly, deletion of CFHR1 and CFHR3 is protective in AMD, but this may 
be due to linkage disequilibrium (see above) with causal variants in the neighbouring CFH 
gene.11 Lores-Motta et al.’s report2 that a CFHR4 SNP, also in strong linkage disequilibrium 
with CFH SNPs, is associated with systemic complement activation, is an intriguing one, 
despite the difficulty of disentangling causal SNPs in the region.  
Since a CFHR4 SNP (rs6685931) and a CFH SNP (rs3753396) are both associated with 
systemic complement activation, the question arises as to whether or not they are also 
associated with AMD, since this would imply the presence or absence, respectively, of a 
causal connection. The observed result, namely that rs6685931 is associated with AMD and 
s3753396 is not associated, is potentially confusing. However there may be a prosaic 
explanation for this apparent discrepancy. The CFH “risk” allele is at substantially lower 
population frequency than the CFHR4 risk SNP. In this case, the study may simply have 
lacked the statistical power to show association of the CFH variant in a relatively small AMD 
cohort. Moreover, AMD is a more complex trait than the C3d/C3 ratio, so SNP effects on the 
disease are likely to be smaller and harder to detect. Alternatively, there could, after all, be 
a disconnect between systemic complement activation and AMD.  
This study highlights some key considerations for those developing complement pathway 
therapeutics. First, while complement activation is not the only genetically influenced 
pathway in AMD, it is further confirmed as a major player. Second, the association of a 
CFHR4 variant with both AMD and increased systemic complement activation merits 
attention, although teasing apart the causal variant(s) will be challenging. Third, systemic 
complement activation surely has a role in AMD, but may influence only part of a complex 
disease process operating on both sides of Bruch’s membrane (Fig. 1). Fourth, genetic 
effects that influence circulating or ocular complement activation may be correlated, in 
which case easily measured systemic markers such as C3d/C3 would be useful for stratifying 
patients in clinical trials.   
In conclusion, several complement pathway SNPs are uncharacteristically common in the 
general population, considering that they exert large effects on complement function. This 
may reflect past evolutionary pressure to resist infectious diseases.12 This factor has 
certainly enabled the detection of core genes and causal pathways in AMD, which emerges 
as a paradigm for using the power of GWAS to elucidate disease.  
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Figure legend 
Figure 1. Blood-retinal interfaces and exposure to the complement system. A, Schematic 
diagram of the outer retina and choroid showing (italics) five potential sites of complement-
mediated damage. 1, RPE tight junctions, form the outer blood-retinal barrier, breached in 
advanced AMD. 2, sub-RPE space: between basal RPE and Bruch’s membrane, becoming 
evident in AMD due to basal deposits and drusen. 3, Bruch’s membrane, a pentalaminar 
membrane interface between blood and retina. 4, fenestrations in the lining of choroidal 
capillaries, facilitate access to Bruch’s membrane by complement proteins. 5, endothelium 
of choroidal capillaries, directly exposed to systemic sources of complement. B, Factor H 
suppresses both fluid-phase and surface complement activation. In the absence of inhibition 
by factor H, C3b amplification leads to conversion of C5 to C5b and formation of the 
cytolytic membrane-attack complex C5b-9n.  C3d is an end-product of complement 
activation (i.e. conversion of C3 to C3b) following factor H/factor I-assisted inactivation. 
CFHR4 may inhibit the action of CFH. *The ratio, soluble (serum) C3d/C3 has been used as a 
proxy for systemic complement activation in a GWAS. 
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